Form 4: Acurx Pharmaceuticals CFO Robert G. Shawah Granted Stock Options

Robert G. Shawah, CFO of Acurx Pharmaceuticals, was granted stock options to purchase 145,000 shares of the company's common stock on February 23, 2024.

Summary

• Robert G. Shawah, the Chief Financial Officer of Acurx Pharmaceuticals, Inc., was granted stock options on February 23, 2024.
• The stock options allow him to purchase 145,000 shares of Acurx's common stock at an exercise price of $3.15.
• The options vest in 36 equal monthly installments starting on the grant date.
• The expiration date for these options is February 22, 2034.
• The filing of this transaction was late due to an inadvertent administrative error.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, but the late filing is a minor negative.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Negatives

• The late filing of the Form 4 indicates a potential weakness in internal controls or compliance procedures.

Risks

• Administrative errors in SEC filings can lead to regulatory scrutiny.
• The value of the stock options is dependent on the future performance of Acurx Pharmaceuticals' stock.

Management Comments

• The late filing was due to an inadvertent administrative error and not any error of the Reporting Person.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• The size of the grant (145,000 shares) would need to be compared to grants made to CFOs at similarly sized pharmaceutical companies to assess its relative magnitude.
• Companies like BioCryst Pharmaceuticals or Spero Therapeutics could be considered as comparables for benchmarking purposes.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates